CNW.DE
co.don AG [CNW.DE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CNW.DE Stock Summary
In the News
CNW.DE Financial details
Company Rating
-
Market Cap
6.55M
Income
-8.63M
Revenue
8.21M
Book val./share
245.96
Cash/share
63.3
Dividend
-
Dividend %
-
Employees
134
Optionable
No
Shortable
Yes
Earnings
30 Aug 2021
P/E
0
Forward P/E
-
PEG
-
P/S
0.67
P/B
-
P/C
-
P/FCF
-0.77
Quick Ratio
2.96
Current Ratio
3.18
Debt / Equity
0.96
LT Debt / Equity
0.89
-
-
EPS (TTM)
-0.55
EPS next Y
-
EPS next Q
-
EPS this Y
50937.5%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
255.41%
Revenue last 5Y
10.39%
Revenue Q/Q
-99.9%
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
-35%
ROE
-49%
ROC
-0.36%
Gross Margin
94%
Oper. Margin
-86%
Profit Margin
-95%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.245-2.35
52W High
-
52W Low
-
RSI
-
Rel Volume
3.9
Avg Volume
8.01K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
1.752
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
CNW.DE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.61 | 0.54 | 0.55 | 0.36 | 429.41 | |
| Net income per share | -0.72 | -0.6 | -1.01 | -0.8 | -408.3 | |
| Operating cash flow per share | -0.6 | -0.78 | -0.76 | -0.54 | -348.37 | |
| Free cash flow per share | -1.01 | -1.44 | -1.07 | -0.58 | -370.19 | |
| Cash per share | 1.3 | 0.98 | 0.33 | 0.53 | 289.19 | |
| Book value per share | 1.66 | 1.21 | 0.92 | 1.19 | 769.5 | |
| Tangible book value per share | 1.65 | 1.16 | 0.84 | 1.17 | 748.35 | |
| Share holders equity per share | 1.66 | 1.21 | 0.92 | 1.19 | 769.5 | |
| Interest debt per share | 0 | 0.65 | 1.13 | 0.56 | 312.19 | |
| Market cap | 118.81M | 61.26M | 42.62M | 40.47M | 37.44K | |
| Enterprise value | 116.16M | 60.53M | 48.15M | 37.32M | -255.56K | |
| P/E ratio | -16.84 | -9.77 | -3.38 | -2.92 | 0 | |
| Price to sales ratio | 19.87 | 10.75 | 6.22 | 6.49 | 0 | |
| POCF ratio | -20.21 | -7.53 | -4.47 | -4.28 | 0 | |
| PFCF ratio | -12.08 | -4.05 | -3.18 | -4 | 0 | |
| P/B Ratio | 7.34 | 4.84 | 3.7 | 1.96 | 0 | |
| PTB ratio | 7.34 | 4.84 | 3.7 | 1.96 | 0 | |
| EV to sales | 19.42 | 10.63 | 7.02 | 5.99 | -0.03 | |
| Enterprise value over EBITDA | -17.09 | -7.29 | -5.59 | -4.05 | 0.04 | |
| EV to operating cash flow | -19.76 | -7.44 | -5.05 | -3.95 | 0.03 | |
| EV to free cash flow | -11.82 | -4 | -3.6 | -3.69 | 0.03 | |
| Earnings yield | -0.06 | -0.1 | -0.3 | -0.34 | -248.96 | |
| Free cash flow yield | -0.08 | -0.25 | -0.31 | -0.25 | -225.72 | |
| Debt to equity | 0 | 0.75 | 0.83 | 0.29 | 0.36 | |
| Debt to assets | 0 | 0.35 | 0.39 | 0.21 | 0.24 | |
| Net debt to EBITDA | 0.39 | 0.09 | -0.64 | 0.34 | 0.04 | |
| Current ratio | 12.95 | 2.54 | 1.79 | 3.97 | 3.18 | |
| Interest coverage | 0 | 3.2 | -2.08 | -2.7 | -9.58 | |
| Income quality | 0.83 | 1.3 | 0.75 | 0.68 | 0.85 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.33 | 0.27 | 0.2 | 0.17 | 0.16 | |
| Research and developement to revenue | 0 | 0.29 | 0.01 | 0.02 | 0 | |
| Intangibles to total assets | 0.01 | 0.02 | 0.04 | 0.01 | 0.02 | |
| Capex to operating cash flow | 0.67 | 0.86 | 0.41 | 0.07 | 0.06 | |
| Capex to revenue | -0.66 | -1.23 | -0.56 | -0.11 | -0.05 | |
| Capex to depreciation | -16.01 | -9.76 | -4.67 | -0.77 | -0.41 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 5.21 | 4.04 | 4.58 | 4.62 | 2.66K | |
| ROIC | -0.47 | -0.43 | -0.38 | -0.33 | -0.33 | |
| Return on tangible assets | -0.38 | -0.23 | -0.53 | -0.48 | -0.36 | |
| Graham Net | 1.03 | -0.42 | -0.6 | 0.14 | -5.87 | |
| Working capital | 12.65M | 7.25M | 2.83M | 8.49M | 6.5M | |
| Tangible asset value | 16.03M | 12.12M | 10.46M | 20.32M | 17.08M | |
| Net current asset value | 10.94M | -2.8M | -6.92M | 2.94M | 726K | |
| Invested capital | 0 | 0.75 | 0.83 | 0.29 | 0.36 | |
| Average receivables | 0 | 0 | 959K | 1.85M | 2.02M | |
| Average payables | 702.52K | 1.15M | 1.26M | 817.5K | 721K | |
| Average inventory | 247.42K | 293.15K | 291.5K | 379.5K | 507K | |
| Days sales outstanding | 0 | 0 | 102.11 | 104.29 | 84.3 | |
| Days payables outstanding | 601.47 | 616.55 | 734.35 | 333.82 | 548.84 | |
| Days of inventory on hand | 284.25 | 85.5 | 271.58 | 206.42 | 421.15 | |
| Receivables turnover | 0 | 0 | 3.57 | 3.5 | 4.33 | |
| Payables turnover | 0.61 | 0.59 | 0.5 | 1.09 | 0.67 | |
| Inventory turnover | 1.28 | 4.27 | 1.34 | 1.77 | 0.87 | |
| ROE | -0.44 | -0.5 | -1.1 | -0.67 | -0.53 | |
| Capex per share | -0.41 | -0.67 | -0.31 | -0.04 | -21.81 |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.07 | 0.14 | 0.14 | 0.06 | 0.06 | |
| Net income per share | -0.14 | -0.07 | -0.07 | -0.21 | -0.21 | |
| Operating cash flow per share | -0.12 | -0.06 | -0.06 | -0.09 | -0.09 | |
| Free cash flow per share | -0.12 | -0.06 | -0.06 | -0.09 | -0.09 | |
| Cash per share | 0.17 | 0 | 0.28 | 0 | 63.3 | |
| Book value per share | 0.65 | 0 | 0.75 | 0 | 245.96 | |
| Tangible book value per share | 0.65 | 0 | 0.73 | 0 | 245.96 | |
| Share holders equity per share | 0.65 | 0 | 0.75 | 0 | 245.96 | |
| Interest debt per share | 0.27 | 0 | 0.25 | 0 | 229.42 | |
| Market cap | 65.43M | 43.11M | 38.63M | 37.53M | 16.78K | |
| Enterprise value | 68.13M | 0 | 38.34M | 0 | 5.03M | |
| P/E ratio | -5.29 | -6.88 | -6.17 | -1.71 | -0.76 | |
| Price to sales ratio | 40.63 | 13.1 | 11.74 | 23.04 | 10.3 | |
| POCF ratio | -25.26 | -31.09 | -27.86 | -15.08 | -6.74 | |
| PFCF ratio | -24.3 | -30.97 | -27.75 | -15.02 | -6.72 | |
| P/B Ratio | 4.55 | 0 | 2.2 | 0 | 0 | |
| PTB ratio | 4.55 | 0 | 2.2 | 0 | 0 | |
| EV to sales | 42.31 | 0 | 11.65 | 0 | 3.09K | |
| Enterprise value over EBITDA | -24.39 | 0 | -36.39 | 0 | -1.62K | |
| EV to operating cash flow | -26.31 | 0 | -27.65 | 0 | -2.02K | |
| EV to free cash flow | -25.3 | 0 | -27.54 | 0 | -2.01K | |
| Earnings yield | -0.05 | -0.04 | -0.04 | -0.15 | -0.33 | |
| Free cash flow yield | -0.04 | -0.03 | -0.04 | -0.07 | -0.15 | |
| Debt to equity | 0.43 | 0 | 0.36 | 0 | 0.96 | |
| Debt to assets | 0.27 | 0 | 0.24 | 0 | 0.4 | |
| Net debt to EBITDA | -0.97 | 0 | 0.28 | 0 | -1.62K | |
| Current ratio | 2.11 | 0 | 3.18 | 0 | 1.05 | |
| Interest coverage | 12.92 | 5.11 | 3.12 | 18.86 | 0.02 | |
| Income quality | 0.84 | 0.89 | 0.89 | 0.45 | 0.45 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0.87 | 0.87 | 0 | 0 | |
| Research and developement to revenue | 0 | 0.07 | 0.07 | 0 | 0 | |
| Intangibles to total assets | 0.01 | 0 | 0.02 | 0 | 0 | |
| Capex to operating cash flow | 0.04 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.06 | 0 | 0 | -0.01 | -0.01 | |
| Capex to depreciation | -0.43 | -0.01 | -0.01 | -0.03 | -0.03 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.43 | 0 | 1.06 | 0 | 33.68 | |
| ROIC | -0.13 | 0 | -0.03 | 0 | 0 | |
| Return on tangible assets | -0.14 | 0 | -0.06 | 0 | 0 | |
| Graham Net | -0.15 | 0 | -0.01 | 0 | -233.05 | |
| Working capital | 2.77M | 0 | 6.5M | 0 | 159K | |
| Tangible asset value | 14.1M | 0 | 17.08M | 0 | 6.59M | |
| Net current asset value | -2.92M | 0 | 726K | 0 | -5.69M | |
| Invested capital | 0.43 | 0 | 0.36 | 0 | 0.96 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 57.22 | 0 | 61.91 | 0 | 51.1K | |
| Days payables outstanding | 216.72 | 0 | 98.72 | 0 | 172.95K | |
| Days of inventory on hand | 267.41 | 0 | 75.75 | 0 | 310.65K | |
| Receivables turnover | 1.57 | 0 | 1.45 | 0 | 0 | |
| Payables turnover | 0.42 | 0 | 0.91 | 0 | 0 | |
| Inventory turnover | 0.34 | 0 | 1.19 | 0 | 0 | |
| ROE | -0.22 | 0 | -0.09 | 0 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
CNW.DE Frequently Asked Questions
What is co.don AG stock symbol ?
co.don AG is a DE stock and trading under the symbol CNW.DE
What is co.don AG stock quote today ?
co.don AG stock price is $- today.
Is co.don AG stock public?
Yes, co.don AG is a publicly traded company.
Company Profile
- Volume Average 8.01K
- Market Capitalization 6.55M
- Employee 134
- CEO Dr. Xing Zhao
- Headquarters Teltow,DE
- IPO Date 2001-02-14
-
Website
https://www.codon.de 
co.don AG, a biopharmaceutical company, develops, produces, and markets cell-based pharmaceutical products for joint preservation and the regenerative treatment of articular cartilage defects worldwide. It offers Spherox, a three dimensional chondrocyte product that is used to treat cartilage defects in adult knee joints; and co.don chondrosphere for the treatment of cartilage defects in the hip, ankle, shoulder and elbow, and knees of younger patients. The company serves accident and orthopedic surgeons. co.don AG was founded in 1993 and is headquartered in Teltow, Germany.
